Using Autologous Tumor-Infiltrating Lymphocytes to Mediate Tumor Regression: Promising Outcomes in Experimental ResearchJuly 30, 2018
Experimental research may provide a blue print for the treatment of many types of cancer.
Postapproval studies are needed to further characterize the risk and long-term safety of immune checkpoint inhibition.
Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.
The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.
Although checkpoint inhibition is altering the landscape of oncologic care, there is a low response rate to treatment.
Study findings suggest that some clinicians are using immunotherapies in the types of patients not included in clinical trials.
Researchers collected ctDNA samples from patients with varying cancer types to determine whether liquid biopsies may help to predict response to checkpoint inhibition.
Clinicians continue to learn about which patients will benefit most from different immunotherapy treatments, and how dosing can effect adverse events.
After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.
Does the failure of pembrolizumab in multiple myeloma clinical trials imply checkpoint inhibition is unlikely to work for patients with the disease?
One (4.2%) patient achieved complete response, and 7 patients (29.2%) achieved durable partial responses. The overall response rate (ORR) was 33.3% (95% CI, 15.6%-55.3%).
Developments in deep sequencing genomic technologies and bioinformatics have made it possible to identify mutations in melanoma and to predict targetable neoantigens.
Nivolumab demonstrated an overall response rate of 32% in all patients, including 2 patients who exhibited a complete response and 22 patients who had partial responses.
Researchers at the University of Miami in Florida are evaluating whether a partially matured dendritic cell vaccine is safe and effective for patients with glioma or glioblastoma.
In this question-and-answer session, Cancer Therapy Advisor asked Dr Iacovelli about his team's recent review regarding the future of personalizing immunotherapy for RCC.
Combining nivolumab with ipilimumab is safe, efficacious, and potentially improves overall survival among patients with metastatic renal cell carcinoma.
Nivolumab, a monoclonal antibody targeting PD-1, does not improve OS among patients with advanced melanoma whose disease progresses after receiving ipilimumab.
Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.
Vaccines targeting multiple myeloma antigens offer a promising therapeutic approach by helping the immune system to fight off cancer cells.
Maintenance pembrolizumab does not prolong progression-free survival, though it may improve overall survival, among patients with extensive-stage small-cell lung cancer.
Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.
Researchers call for additional clinical trials investigating radiotherapy followed by immune checkpoint blockade for patients with NSCLC.
Neoadjuvant nivolumab is safe and provides a comparable pathologic response to that with cisplatin-based neoadjuvant chemotherapy in resectable non-small cell lung cancer.
Immune checkpoint inhibitors may be effective for treating elderly patients with melanoma without dramatically increasing toxicity.
Two vaccine therapies, TG4010 and CIMAvax-EGF, show promise for treating lung cancer. Developed and approved for use in Cuba, CIMAvax-EGF is now undergoing clinical study in the United States.
Pembrolizumab may be an effective treatment for patients with a rare subtype of diffuse large B-cell lymphoma, which usually carries a poor prognosis.
The FDA approved pembrolizumab in combination with pemetrexed and carboplatin as a first-line treatment for metastatic lung cancer.
It's unclear whether the FDA will revoke its May 2016 approval of atezolizumab, which was based on tumor response rate and duration of response in the phase 2 open-label IMvigor210 study.
A subset of patients with advanced endometrial cancer experienced durable partial responses to pembrolizumab.
Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?